Paul J. Mosca

3.2k total citations
83 papers, 2.1k citations indexed

About

Paul J. Mosca is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Paul J. Mosca has authored 83 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 30 papers in Immunology and 24 papers in Molecular Biology. Recurrent topics in Paul J. Mosca's work include Cutaneous Melanoma Detection and Management (29 papers), Immunotherapy and Immune Responses (28 papers) and CAR-T cell therapy research (18 papers). Paul J. Mosca is often cited by papers focused on Cutaneous Melanoma Detection and Management (29 papers), Immunotherapy and Immune Responses (28 papers) and CAR-T cell therapy research (18 papers). Paul J. Mosca collaborates with scholars based in United States, Australia and Russia. Paul J. Mosca's co-authors include Michael A. Morse, H. Kim Lyerly, Timothy M. Clay, Amy Hobeika, Joyce L. Hamlin, Douglas S. Tyler, Peter A. Dijkwel, Gavin P. Robertson, Georgia M. Beasley and Smita K. Nair and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Paul J. Mosca

81 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul J. Mosca United States 25 1.1k 816 757 244 220 83 2.1k
David Chao Taiwan 23 601 0.6× 682 0.8× 576 0.8× 275 1.1× 378 1.7× 72 2.2k
Douglas M. Potter United States 33 1.6k 1.5× 1.4k 1.8× 1.4k 1.8× 309 1.3× 264 1.2× 64 3.6k
Arundhati Ghosh United States 24 557 0.5× 1.1k 1.3× 1.3k 1.7× 590 2.4× 226 1.0× 60 2.9k
Pei‐Ling Hsu United States 27 385 0.4× 504 0.6× 742 1.0× 194 0.8× 128 0.6× 78 2.1k
Giuseppe Tridente Italy 29 413 0.4× 926 1.1× 622 0.8× 178 0.7× 353 1.6× 129 2.6k
Cécile Le Page Canada 28 1.1k 1.0× 995 1.2× 1.2k 1.6× 336 1.4× 265 1.2× 62 3.1k
Henrik Schmidt Denmark 27 2.6k 2.4× 1.8k 2.2× 1.1k 1.5× 353 1.4× 155 0.7× 96 3.6k
Subramaniam Malarkannan United States 35 1.1k 1.0× 2.9k 3.5× 969 1.3× 142 0.6× 334 1.5× 97 3.9k
Howard Streicher United States 27 1.8k 1.6× 1.2k 1.4× 910 1.2× 760 3.1× 475 2.2× 105 3.5k
S. von Kleist Germany 33 1.3k 1.2× 993 1.2× 1.3k 1.7× 263 1.1× 249 1.1× 113 3.5k

Countries citing papers authored by Paul J. Mosca

Since Specialization
Citations

This map shows the geographic impact of Paul J. Mosca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul J. Mosca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul J. Mosca more than expected).

Fields of papers citing papers by Paul J. Mosca

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul J. Mosca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul J. Mosca. The network helps show where Paul J. Mosca may publish in the future.

Co-authorship network of co-authors of Paul J. Mosca

This figure shows the co-authorship network connecting the top 25 collaborators of Paul J. Mosca. A scholar is included among the top collaborators of Paul J. Mosca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul J. Mosca. Paul J. Mosca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Salama, April K.S., et al.. (2023). Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec. JAAD Case Reports. 40. 53–57. 3 indexed citations
2.
Farrow, Norma E., Jina Kim, Steven E. Wolf, et al.. (2022). Examining the role of wide excision margins in pediatric melanoma: A National Cancer Database analysis. Pediatric Blood & Cancer. 69(11). e29884–e29884. 2 indexed citations
3.
Salama, April K.S., Manisha Palta, Christel Rushing, et al.. (2020). Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma. Clinical Cancer Research. 27(5). 1287–1295. 4 indexed citations
4.
Jones, David C., Visakha Suresh, Brent A. Hanks, et al.. (2020). The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma. Surgical Oncology. 35. 533–539. 4 indexed citations
5.
Masoud, Sabran, et al.. (2020). Retreatment with Talimogene Laherparepvec for Advanced Melanoma. Immunotherapy. 12(16). 1167–1172. 1 indexed citations
6.
Masoud, Sabran, et al.. (2019). Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size. Annals of Surgical Oncology. 26(13). 4633–4641. 27 indexed citations
7.
Josyula, Srirama, Alicia M. Terando, John H. Howard, et al.. (2018). Does the number of sentinel lymph nodes removed affect the false negative rate for head and neck melanoma?. Journal of Surgical Oncology. 117(7). 1584–1588. 14 indexed citations
8.
Cardones, Adela R., et al.. (2018). The impact of transplant rejection on cutaneous squamous cell carcinoma in renal transplant recipients. Clinical and Experimental Dermatology. 44(3). 265–269.
9.
Mosca, Paul J., et al.. (2017). The changing landscape of dermatology practice: melanoma and pump-probe laser microscopy. Lasers in Medical Science. 32(8). 1935–1939. 1 indexed citations
10.
Kim, Jina, Zhifei Sun, Brian C. Gulack, et al.. (2016). Sentinel lymph node biopsy is a prognostic measure in pediatric melanoma. Journal of Pediatric Surgery. 51(6). 986–990. 26 indexed citations
11.
Gowda, Raghavendra, et al.. (2016). Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy. Biotechnology Advances. 34(5). 565–577. 45 indexed citations
12.
Beasley, Georgia M., Paul J. Speicher, Paul J. Mosca, et al.. (2014). Immunotherapy Following Regional Chemotherapy Treatment of Advanced Extremity Melanoma. Annals of Surgical Oncology. 21(8). 2525–2531. 8 indexed citations
13.
Oldan, Jorge D., Olga James, Paul J. Mosca, Douglas S. Tyler, & Salvador Borges‐Neto. (2014). Two-day lymphoscintigraphic imaging for melanoma. Nuclear Medicine Communications. 35(8). 870–875. 3 indexed citations
14.
Dannull, Jens, Nancy Haley, Gary E. Archer, et al.. (2013). Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. Journal of Clinical Investigation. 123(7). 3135–3145. 58 indexed citations
15.
Clawson, Gary A., Eric T. Kimchi, Susan D. Patrick, et al.. (2012). Circulating Tumor Cells in Melanoma Patients. PLoS ONE. 7(7). e41052–e41052. 78 indexed citations
16.
Sharma, Arati, Arun Sharma, SubbaRao V. Madhunapantula, et al.. (2009). Targeting Akt3 Signaling in Malignant Melanoma Using Isoselenocyanates. Clinical Cancer Research. 15(5). 1674–1685. 82 indexed citations
17.
Mosca, Paul J., Timothy M. Clay, H. Kim Lyerly, & Michael A. Morse. (2003). CURRENT STATUS OF DENDRITIC CELL IMMUNOTHERAPY OF MALIGNANCIES. International Reviews of Immunology. 22(3-4). 255–281. 9 indexed citations
18.
Morse, Michael A., Paul J. Mosca, Timothy M. Clay, & H. Kim Lyerly. (2002). Dendritic cell maturation in active immunotherapy strategies. Expert Opinion on Biological Therapy. 2(1). 35–43. 34 indexed citations
19.
Mosca, Paul J., et al.. (1995). Mimosine, a novel inhibitor of DNA replication, binds to a 50 kDa protein in Chinese hamster cells. Nucleic Acids Research. 23(2). 261–268. 20 indexed citations
20.
Hamlin, Joyce L., et al.. (1993). Initiation of Replication at a Mammalian Chromosomal Origin. Cold Spring Harbor Symposia on Quantitative Biology. 58(0). 467–474. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Chao Breakdown of academic impact, for papers by Douglas M. Potter Breakdown of academic impact, for papers by Arundhati Ghosh Breakdown of academic impact, for papers by Pei‐Ling Hsu Breakdown of academic impact, for papers by Giuseppe Tridente Breakdown of academic impact, for papers by Cécile Le Page Breakdown of academic impact, for papers by Henrik Schmidt Breakdown of academic impact, for papers by Subramaniam Malarkannan Breakdown of academic impact, for papers by Howard Streicher Breakdown of academic impact, for papers by S. von Kleist
Rankless by CCL
2026